Unicycive regains Nasdaq minimum market value compliance

Unicycive Therapeutics, Inc.

Received non-compliance notice on May 17, 2023 for MVLS below $35M.
MVLS remained above $35M for 10 consecutive business days ending July 24.
Nasdaq confirmed compliance on July 25, 2023.
Delisting risk removed; stock continues trading on Nasdaq Capital Market.

item 8.01

Unicycive Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-059806

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.